Redhill Historical Balance Sheet

RDHL Stock

USD 2.79 0.01 0.36%

Trend analysis of Redhill Biopharma balance sheet accounts such as Accounts Payable of 4.2 M, Cash of 6.1 M, Long Term Debt of 101 M or Common Stock Shares Outstanding of 7.8 M provides information on Redhill Biopharma's total assets, liabilities, and equity, which is the actual value of Redhill Biopharma to its prevalent stockholders. By breaking down trends over time using Redhill Biopharma balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Redhill Biopharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Redhill Biopharma is a good buy for the upcoming year.

Redhill Biopharma Inventory

5.3 Million

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Redhill Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.

About Redhill Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Redhill Biopharma at a specified time, usually calculated after every quarter, six months, or one year. Redhill Biopharma Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Redhill Biopharma and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Redhill currently owns. An asset can also be divided into two categories, current and non-current.

Redhill Biopharma Balance Sheet Chart

At this time, Redhill Biopharma's Common Stock is quite stable compared to the past year. Property Plant Equipment is expected to rise to about 5.1 M this year, although the value of Other Liabilities will most likely fall to about 2.8 M.

Total Assets Other Current Liab Total Current Liabilities Other Liab

Add Fundamental

Total Assets

Total assets refers to the total amount of Redhill Biopharma assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Redhill Biopharma books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Redhill Biopharma balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Redhill Biopharma are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Redhill Biopharma's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Redhill Biopharma current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Redhill Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.At this time, Redhill Biopharma's Common Stock is quite stable compared to the past year. Property Plant Equipment is expected to rise to about 5.1 M this year, although the value of Other Liabilities will most likely fall to about 2.8 M.

	2022	2023	2024	2025 (projected)
Other Current Liabilities	77.0M	15.2M	17.5M	19.1M
Total Assets	158.9M	23.0M	26.5M	25.2M

Other Current Liab Total Assets

Redhill Biopharma balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Other Liab	Accounts Payable	Cash	Long Term Debt	Common Stock Shares Outstanding	Short Term Investments	Other Current Assets	Total Liab	Preferred Stock Total Equity	Intangible Assets	Common Stock	Property Plant Equipment	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Non Current Liabilities Total
Total Assets		0.87	0.75	0.55	0.86	0.54	0.42	-0.2	0.02	0.19	0.91	0.24	0.95	-0.27	0.5	-0.21	0.83	0.75	-0.5	0.94	0.51	0.42	0.34	0.9	0.48	0.81
Other Current Liab	0.87		0.91	0.63	0.76	0.16	0.58	0.13	-0.33	0.08	0.99	-0.02	0.93	0.06	0.68	-0.65	0.89	0.95	-0.73	0.92	0.6	0.73	-0.12	0.99	0.62	0.73
Total Current Liabilities	0.75	0.91		0.48	0.49	0.12	0.5	0.09	-0.3	0.19	0.91	0.0	0.79	0.03	0.57	-0.71	0.88	0.92	-0.67	0.75	0.32	0.61	-0.13	0.91	0.53	0.42
Other Liab	0.55	0.63	0.48		0.6	0.31	0.44	0.34	-0.48	-0.16	0.61	-0.11	0.63	0.3	0.62	-0.39	0.53	0.48	-0.57	0.63	0.57	0.68	-0.12	0.6	0.51	0.6
Accounts Payable	0.86	0.76	0.49	0.6		0.39	0.55	0.1	0.03	0.06	0.74	-0.02	0.85	0.03	0.66	-0.1	0.68	0.58	-0.6	0.87	0.6	0.58	0.24	0.74	0.65	0.9
Cash	0.54	0.16	0.12	0.31	0.39		-0.02	-0.45	0.29	-0.06	0.24	0.37	0.33	-0.48	-0.08	0.48	0.21	-0.07	0.06	0.33	0.09	-0.21	0.81	0.22	0.03	0.34
Long Term Debt	0.42	0.58	0.5	0.44	0.55	-0.02		0.66	-0.3	-0.25	0.51	-0.46	0.49	0.61	0.88	-0.41	0.65	0.47	-0.9	0.49	0.08	0.81	-0.23	0.5	0.95	0.35
Common Stock Shares Outstanding	-0.2	0.13	0.09	0.34	0.1	-0.45	0.66		-0.38	-0.2	-0.01	-0.79	-0.08	1.0	0.67	-0.41	0.11	0.07	-0.69	-0.08	-0.01	0.76	-0.55	-0.01	0.7	-0.11
Short Term Investments	0.02	-0.33	-0.3	-0.48	0.03	0.29	-0.3	-0.38		0.63	-0.3	0.27	-0.24	-0.38	-0.44	0.74	-0.31	-0.39	0.32	-0.24	-0.25	-0.52	0.78	-0.3	-0.19	-0.19
Other Current Assets	0.19	0.08	0.19	-0.16	0.06	-0.06	-0.25	-0.2	0.63		0.11	0.16	0.07	-0.21	-0.16	0.11	0.05	0.17	0.07	0.05	0.02	-0.11	0.32	0.11	-0.12	-0.08
Total Liab	0.91	0.99	0.91	0.61	0.74	0.24	0.51	-0.01	-0.3	0.11		0.1	0.96	-0.08	0.62	-0.59	0.91	0.94	-0.64	0.95	0.56	0.62	-0.04	1.0	0.53	0.75
Preferred Stock Total Equity	0.24	-0.02	0.0	-0.11	-0.02	0.37	-0.46	-0.79	0.27	0.16	0.1		0.15	-0.79	-0.46	0.26	-0.02	0.04	0.39	0.15	0.04	-0.55	0.42	0.1	-0.5	0.14
Intangible Assets	0.95	0.93	0.79	0.63	0.85	0.33	0.49	-0.08	-0.24	0.07	0.96	0.15		-0.15	0.63	-0.42	0.89	0.87	-0.56	1.0	0.59	0.57	0.05	0.96	0.51	0.87
Common Stock	-0.27	0.06	0.03	0.3	0.03	-0.48	0.61	1.0	-0.38	-0.21	-0.08	-0.79	-0.15		0.61	-0.39	0.03	0.0	-0.64	-0.15	-0.04	0.72	-0.57	-0.08	0.65	-0.16
Property Plant Equipment	0.5	0.68	0.57	0.62	0.66	-0.08	0.88	0.67	-0.44	-0.16	0.62	-0.46	0.63	0.61		-0.52	0.77	0.6	-0.9	0.63	0.2	0.91	-0.35	0.61	0.92	0.51
Total Stockholder Equity	-0.21	-0.65	-0.71	-0.39	-0.1	0.48	-0.41	-0.41	0.74	0.11	-0.59	0.26	-0.42	-0.39	-0.52		-0.54	-0.77	0.57	-0.4	-0.33	-0.69	0.77	-0.61	-0.36	-0.18
Property Plant And Equipment Net	0.83	0.89	0.88	0.53	0.68	0.21	0.65	0.11	-0.31	0.05	0.91	-0.02	0.89	0.03	0.77	-0.54		0.87	-0.71	0.88	0.23	0.63	-0.07	0.9	0.66	0.61
Net Debt	0.75	0.95	0.92	0.48	0.58	-0.07	0.47	0.07	-0.39	0.17	0.94	0.04	0.87	0.0	0.6	-0.77	0.87		-0.62	0.85	0.51	0.65	-0.3	0.95	0.47	0.61
Retained Earnings	-0.5	-0.73	-0.67	-0.57	-0.6	0.06	-0.9	-0.69	0.32	0.07	-0.64	0.39	-0.56	-0.64	-0.9	0.57	-0.71	-0.62		-0.55	-0.21	-0.91	0.27	-0.64	-0.95	-0.37
Non Current Assets Total	0.94	0.92	0.75	0.63	0.87	0.33	0.49	-0.08	-0.24	0.05	0.95	0.15	1.0	-0.15	0.63	-0.4	0.88	0.85	-0.55		0.61	0.57	0.05	0.94	0.51	0.9
Non Currrent Assets Other	0.51	0.6	0.32	0.57	0.6	0.09	0.08	-0.01	-0.25	0.02	0.56	0.04	0.59	-0.04	0.2	-0.33	0.23	0.51	-0.21	0.61		0.43	-0.1	0.57	0.12	0.75
Other Assets	0.42	0.73	0.61	0.68	0.58	-0.21	0.81	0.76	-0.52	-0.11	0.62	-0.55	0.57	0.72	0.91	-0.69	0.63	0.65	-0.91	0.57	0.43		-0.48	0.63	0.85	0.46
Cash And Short Term Investments	0.34	-0.12	-0.13	-0.12	0.24	0.81	-0.23	-0.55	0.78	0.32	-0.04	0.42	0.05	-0.57	-0.35	0.77	-0.07	-0.3	0.27	0.05	-0.1	-0.48		-0.06	-0.14	0.1
Net Receivables	0.9	0.99	0.91	0.6	0.74	0.22	0.5	-0.01	-0.3	0.11	1.0	0.1	0.96	-0.08	0.61	-0.61	0.9	0.95	-0.64	0.94	0.57	0.63	-0.06		0.52	0.75
Common Stock Total Equity	0.48	0.62	0.53	0.51	0.65	0.03	0.95	0.7	-0.19	-0.12	0.53	-0.5	0.51	0.65	0.92	-0.36	0.66	0.47	-0.95	0.51	0.12	0.85	-0.14	0.52		0.37
Non Current Liabilities Total	0.81	0.73	0.42	0.6	0.9	0.34	0.35	-0.11	-0.19	-0.08	0.75	0.14	0.87	-0.16	0.51	-0.18	0.61	0.61	-0.37	0.9	0.75	0.46	0.1	0.75	0.37

Click cells to compare fundamentals

Redhill Biopharma Account Relationship Matchups

Redhill Biopharma balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	180.2M	181.2M	158.9M	23.0M	26.5M	25.2M
Other Current Liab	60.0M	68.2M	77.0M	15.2M	17.5M	19.1M
Total Current Liabilities	73.2M	81.5M	197.5M	19.2M	22.1M	33.1M
Other Liab	844K	500K	7.9M	4.6M	5.3M	2.8M
Accounts Payable	11.6M	11.7M	4.2M	3.3M	3.8M	4.2M
Cash	29.3M	29.5M	20.0M	5.6M	6.4M	6.1M
Common Stock Shares Outstanding	910.7K	1.2M	1.5M	6.5M	7.4M	7.8M
Short Term Investments	18.8M	498K	8.5M	790.0K	908.5K	863.1K
Other Current Assets	4.9M	3.8M	17.0M	2.1M	2.4M	2.3M
Total Liab	166.4M	172.3M	207.3M	21.0M	24.1M	22.9M
Intangible Assets	87.9M	71.6M	65.6M	5.6M	6.4M	6.1M
Common Stock	1.1M	1.5M	2.8M	21.4M	24.7M	25.9M
Property Plant Equipment	163K	3.8M	5.7M	4.2M	4.9M	5.1M
Total Stockholder Equity	13.9M	8.9M	(48.4M)	2.1M	1.9M	1.8M
Property Plant And Equipment Net	5.7M	4.2M	7.2M	1.2M	1.4M	2.0M
Net Debt	57.6M	58.3M	102.7M	(4.4M)	(5.1M)	(4.8M)
Retained Earnings	(280.3M)	(367.9M)	(433.9M)	(407.7M)	(367.0M)	(348.6M)
Non Current Assets Total	109.7M	92.0M	73.0M	6.9M	7.9M	7.5M
Non Currrent Assets Other	16.2M	16.2M	150K	34.0	39.1	37.14
Cash And Short Term Investments	29.8M	38.0M	20.0M	6.4M	7.3M	6.9M
Net Receivables	29.3M	32.5M	37.9M	3.3M	3.8M	3.6M
Liabilities And Stockholders Equity	180.2M	181.2M	158.9M	23.0M	26.5M	25.2M
Non Current Liabilities Total	93.1M	90.8M	9.8M	1.7M	2.0M	1.9M
Inventory	6.5M	14.8M	11.0M	4.4M	5.0M	5.3M
Other Stockholder Equity	293.1M	375.2M	382.6M	388.4M	446.6M	469.0M
Property Plant And Equipment Gross	5.7M	5.0M	8.3M	2.4M	2.8M	2.2M
Total Current Assets	70.5M	89.2M	85.9M	16.1M	18.6M	17.6M
Net Tangible Assets	45.9M	43.1M	(74.0M)	(62.8M)	(56.5M)	(53.7M)
Net Invested Capital	95.3M	92.5M	66.8M	2.1M	1.9M	1.8M
Net Working Capital	(2.7M)	7.7M	(111.6M)	(3.1M)	(2.8M)	(2.7M)
Capital Stock	1.1M	1.5M	2.8M	21.4M	24.7M	25.9M
Short Long Term Debt Total	86.9M	87.8M	122.7M	1.2M	1.3M	1.3M
Capital Lease Obligations	5.5M	4.2M	7.5M	1.2M	1.1M	1.0M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Redhill Biopharma is a strong investment it is important to analyze Redhill Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Redhill Biopharma's future performance. For an informed investment choice regarding Redhill Stock, refer to the following important reports:

How To Invest In Redhill

Details

Is Redhill Stock a good investment?

Details

What is Redhill Biopharma's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.

You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Redhill Biopharma. If investors know Redhill will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Redhill Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(302.63)

Revenue Per Share

4.733

Quarterly Revenue Growth

(0.28)

Return On Assets

(0.45)

Return On Equity

(17.09)

The market value of Redhill Biopharma is measured differently than its book value, which is the value of Redhill that is recorded on the company's balance sheet. Investors also form their own opinion of Redhill Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Redhill Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Redhill Biopharma's market value can be influenced by many factors that don't directly affect Redhill Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Redhill Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Redhill Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Redhill Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Redhill Historical Balance Sheet

Redhill Biopharma Inventory

5.3 Million

About Redhill Balance Sheet Analysis

Redhill Biopharma Balance Sheet Chart

Total Assets

Total Current Liabilities

Redhill Biopharma balance sheet Correlations

Redhill Biopharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Redhill Biopharma balance sheet Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock	+ 1.0	Common Stock Shares Outstanding
Net Receivables	+ 1.0	Total Liab
Non Current Assets Total	+ 1.0	Intangible Assets
Total Liab	+ 0.99	Other Current Liab
Net Receivables	+ 0.99	Other Current Liab
Intangible Assets	+ 0.96	Total Liab

Common Stock Total Equity	- 0.95	Retained Earnings
Other Assets	- 0.91	Retained Earnings
Retained Earnings	- 0.9	Property Plant Equipment
Retained Earnings	- 0.9	Long Term Debt
Common Stock	- 0.79	Preferred Stock Total Equity
Preferred Stock Total Equity	- 0.79	Common Stock Shares Outstanding